Stockreport

Korro Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Korro Bio, Inc.  (KRRO) 
PDF Nominated KRRO-121 development candidate for the potential treatment of hyperammonemia in patients with urea cycle disorders and hepatic encephalopathyAdvanced GalNAc-co [Read more]